Other Routine +

Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026

Preclinical Validation Meets Liquidity Crunch

By The Northwire Desk — AI Analysis Apr 21, 2026 · 07:30 MDNA · 0.6 MEDICENNA THERAPEUTICS CORP. J

Executive Summary

Medicenna Therapeutics presented preclinical data for MDNA113 at AACR 2026 on April 21, 2026.
The asset is a first-in-class anti-PD-1 x IL-2 bifunctional Superkine designed to be tumor-anchored and conditionally activated.
Non-human primate studies showed MDNA113 was well tolerated at doses up to 50 mg/kg with no dose-limiting adverse findings.
A comparator molecule (anti-PD-1 x IL-2 alpha-biased bispecific) exhibited severe toxicity including vascular leak syndrome at only 1.4 mg/kg.
MDNA113 demonstrated a therapeutic window more than 30-fold higher than the comparator in head-to-head studies.
The data supports an Investigational New Drug (IND) submission expected in the second half of 2026.
Mechanism involves masking domains that attenuate IL-2R agonism by >10,000-fold and tumor anchoring via IL-13Ralpha2 targeting.

Material Impact

The news confirms positive preclinical safety data for MDNA113, de-risking the IND filing timeline planned for H2 2026.
While the data is scientifically robust (superior tolerability vs comparator), it does not resolve the company's immediate liquidity constraints.
Cash runway was reported as ending in Q3 2026 in February 2026 results; with current date April 2026, capital raising or partnership is imminent regardless of this data.
The event (AACR presentation) was announced weeks prior on March 18, 2026, meaning the market had time to price in the expectation of a milestone update.
Positive preclinical results often lead to short-term volatility but rarely sustain long-term rallies without clinical efficacy proof or financing news attached.
The primary risk remains dilution; investors may view this as a catalyst for equity financing rather than organic growth, limiting upside potential relative to downside risk.

MDNA · Price

Company Overview

Medicenna Therapeutics is a clinical-stage biotechnology company focused on immunotherapy assets using Superkine technology.
Flagship Asset (MDNA11): A long-acting IL-2 superkine currently in Phase 1/2 trials (ABILITY-1) for solid tumors and melanoma. Recent data shows ORR of 36% monotherapy and 43% with pembrolizumab.
Secondary Asset (MDNA113): First-in-class anti-PD-1 x IL-2 bifunctional molecule, currently in preclinical stage advancing to IND filing H2 2026.
Third Asset (Bizaxofusp/MDNA55): IL-4 Empowered Superkine targeting glioblastoma; Phase 2b data showed median OS doubling to 13.6 months vs standard care.
The company targets "immunologically cold" solid tumors with high unmet need, aiming for over 2 million patients worldwide.

More from MEDICENNA THERAPEUTICS CORP. J